AMR: AN ECONOMIC PERSPECTIVE

Michele Cecchini
OECD, Health Division
Irrational Use of Antimicrobials is the Norm in OECD Countries

Source: Cecchini & Lee, OECD, forthcoming – please do not cite or quote
AMR has a Large Cost for Healthcare Systems and the Whole Economy

Hospitalised patients with antibiotic-resistant infections costs an additional 10-40k USD

Over half of extra expenditure is due to nursing and medical care

23b USD additional healthcare spending in Europe and North America per year

Source: Cecchini et al., AMR in G7 countries and Beyond, OECD, 2016
OECD Recommendations to Move Forward in the Fight Against AMR

- Coordinating with global partners to efficiently upscale national efforts into a **global action**
- Strengthening existing **surveillance and monitoring** systems
- Adopting globally agreed sets of **measurable targets** on AMR **incidence** and efficient **antibiotic use**
- Strengthening ongoing efforts to **rationalise antibiotics** use and **prevention** of AMR spread
- Fostering **R&D** through a global collaborative **research platform**, and by **delinking development from sales**